Diagnostic efficacy of 99mTc-FAPI SPECT/CT

Evaluation the efficiency of 99mTc-FAPI radiotracer in diagnosis of patients suffering from cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210612051548N5

Enrollment

Registered

2022-01-29

Start date

2022-03-06

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm. Malignant neoplasm

Interventions

Intervention group: The majority of epithelial tumors recruit fibroblasts and other non-malignant cells and activate them into cancer-associated fibroblasts. This often leads to overexpression of the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Volunteering to participate in clinical trials and signing an informed consent form (signed by participant, parent, or legal representative) Patients with suspected or new diagnosed or previously treated malignant tumors Inconclusive findings on imaging modalities.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women The inability or unwillingness of the research participant, parent, or legal representative to provide written informed consent

Design outcomes

Primary

Measure	Time frame
Target/Background ratio of 99mTc-FAPI SPECT/CT in Diagnosis of malignancies. Timepoint: 99mTc-FAPI Imaging at 1and 4 hours after the administration of the Radiotracer. Method of measurement: SPECT/CT scanner.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Assadi

Boushehr University of Medical Sciences

assadipoya@yahoo.com+98 77 3332 0361

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026